INTRODUCTION
Acquired hemophilia is an autoimmune disease characterized by the production of autoantibodies against plasma coagulation factors.
1) It is a rare but potentially life-threatening condition that occurs more commonly in the elderly population.
2) The diagnosis of this condition is under-recognized, and a delay in diagnosis leads to a high mortality rate among these patients. In the elderly group of patients, the unexplained bleeding tendency with isolated prolonged activated partial thromboplastin time (aPTT) should raise high clinical suspicion of acquired hemophilia. Treatment of acquired hemophilia includes acute bleeding control and suppression of the autoimmune process by an immunosuppressive agent.
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CASE REPORT
A 67-year-old man with underlying ischemic heart disease and dyslipidemia presented to the emergency department with spontaneous left leg swelling for a week. There were no complaints of any calf pain or bleeding tendency elsewhere. During the 4th week of the illness, he developed new bruises on both of his hands. There was bleeding from venepuncture site, which did not stop spontaneously. However, there were no changes in the leg hematoma, and the repeated aPTT values still remained high.
On family medicine specialist review, he was referred to hematological team based on clinical suspicion of acquired hemophilia. Upon admission, the patient was actively bleeding from the venepuncture site. Mixing studies with the patient's plasma were performed but the prolonged aPTT failed to correct completely. Further, the patient had a low plasma factor VIII level of 5%. The plasma VIII inhibitors were also detected, and the titre value was found to be 19.6 BU/mL. Lupus anticoagulant was not detected in patient's plasma (Tables 1, 2) .
Following the diagnosis of acquired hemophilia, the patient was subjected to immunosuppressive therapy in the form of high dose prednisolone 1 mg/kg per day (total 70 mg daily) and cyclophosphamide (100 mg once a day). He was later treated with rituximab (375 mg/m 2 on a weekly basis) for a 4-week duration. The patient was also given a short period of inpatient treatment for rehabilitation and rest, allowing the bleeding to stop and hematoma to be resolved. Finally, he was discharged when his aPTT was corrected to normal range.
DISCUSSION
Acquired hemophilia is a rare spontaneous autoimmune disorder caused by the development of antibodies against its own plasma coagulation factors, most commonly factor VIII. reduced factor VIII levels and the presence of factor VIII inhibitor were critical for confirming the diagnosis of acquired hemophilia A ( Figure   1 ). 3, 6) The disease is potentially life-threatening with mortality in the range of 8%-22%, and the patients are at highest risk in the first few weeks following the initial clinical presentation. Mortality remains high among the elderly population, with a rate of 50% at 1 year following diagnosis.
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Treatment of acquired hemophilia includes immediate hemostasis and immunosuppression, and this helps in controlling the autoantibody production. The usual treatment involves administration of a high dose of oral prednisolone at 1 mg/kg combined with oral cyclophosphamide 50-100 mg per day for up to 2 months with regular aPTT monitoring. 3) Most patients respond well to such combination treatment regime, and monitoring of aPTT is sufficient to study the effectiveness of the treatment in patients. It has recently been shown that treatment of acquired hemophilia with rituximab is more effective and well tolerated. It has also been found to be effective in cases where the conventional treatment is either not responsive or recommended. 4) Treatment with rituximab involves the intravenous infusion of 375 mg/m 2 in each administration at weekly interval for a total of 4 weeks.
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Treating patients with this drug has shown promising results, with an increase in plasma factor VIII levels and a corresponding fall in inhibitor titer within the first week of treatment. From the current study, it is evident that at initial presentation, diagnosis of acquired hemophilia is not given a priority; further, the isolated prolonged aPTT finding is often ignored. It is critical for the primary health care provider to perform a complete assessment and be aware of rare yet clinically relevant diseases. Considerable attention should be paid while examining the patient, and appropriate investigations should be carried out without any delay. Implications of under-recognized or delayed diagnosis of such diseases can be disastrous to the patient. Early treatment of diseases, such as acquired hemophilia, can significantly reduce the mortality and morbidity resulting from such conditions, particularly for those effective treatments is available.
